These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29793829)

  • 1. Best practices for the use of intracerebroventricular drug delivery devices.
    Slavc I; Cohen-Pfeffer JL; Gururangan S; Krauser J; Lim DA; Maldaun M; Schwering C; Shaywitz AJ; Westphal M
    Mol Genet Metab; 2018 Jul; 124(3):184-188. PubMed ID: 29793829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration.
    Cohen-Pfeffer JL; Gururangan S; Lester T; Lim DA; Shaywitz AJ; Westphal M; Slavc I
    Pediatr Neurol; 2017 Feb; 67():23-35. PubMed ID: 28089765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies.
    Kramer K; Smith M; Souweidane MM
    Pediatr Blood Cancer; 2014 Sep; 61(9):1590-2. PubMed ID: 24777835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review.
    Kuo A; Smith MT
    J Neurosci Methods; 2014 Aug; 233():166-71. PubMed ID: 24937765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.
    Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT
    Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders.
    Govender T; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Modi G; Naidoo D; Pillay V
    Pharm Dev Technol; 2017 Jun; 22(4):476-486. PubMed ID: 27268737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise and perils of CNS drug delivery: a video debate.
    Gendelman HE; Kabanov A; Linder J
    J Neuroimmune Pharmacol; 2008 Jun; 3(2):58. PubMed ID: 18322803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound.
    Poon C; McMahon D; Hynynen K
    Neuropharmacology; 2017 Jul; 120():20-37. PubMed ID: 26907805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients.
    Peyrl A; Chocholous M; Azizi AA; Czech T; Dorfer C; Mitteregger D; Gojo J; Minichmayr E; Slavc I
    J Neurooncol; 2014 Oct; 120(1):139-45. PubMed ID: 25017328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanocarriers for CNS-targeted drug delivery.
    Micheli MR; Bova R; Magini A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):71-86. PubMed ID: 22283231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
    Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
    Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurological disorders and the blood-brain barrier. Strategies and limitations for drug delivery to the brain].
    Domínguez A; Álvarez A; Suárez-Merino B; Goñi-de-Cerio F
    Rev Neurol; 2014 Mar; 58(5):213-24. PubMed ID: 24570360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent encephaloclastic cyst induced by intraventricular topotecan.
    Mella DB; Kamiya-Matsuoka C; Liao B; Tummala S; de Groot J
    J Neurol Sci; 2015 Feb; 349(1-2):52-3. PubMed ID: 25598491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery.
    Dong J; Shang Y; Inthavong K; Chan HK; Tu J
    Pharm Res; 2017 Dec; 35(1):5. PubMed ID: 29288465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics.
    Bourganis V; Kammona O; Alexopoulos A; Kiparissides C
    Eur J Pharm Biopharm; 2018 Jul; 128():337-362. PubMed ID: 29733950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.